Allogene Therapeutics, Inc. Annual Report - A Closer Look for Investors

Allogene Therapeutics stands at the forefront of cancer treatment, developing innovative "off-the-shelf" cell therapies. This in-depth review provides a clear and comprehensive understanding of the company's operations, financial health, and future prospects for the fiscal year ended December 31, 2025, with comparisons to 2024. Use this summary to assess how Allogene aligns with your investment goals.

1. Business Overview

Allogene Therapeutics is a clinical-stage biotechnology company that develops innovative allogeneic (off-the-shelf) CAR T-cell therapies for cancer. Unlike traditional CAR T-cell therapies, which use a patient's own cells, Allogene's approach creates readily available treatments from healthy donors. This method potentially offers greater accessibility, scalability, and faster treatment initiation for patients. The company primarily focuses on hematologic malignancies (blood cancers) and solid tumors.

Allogene's competitive advantage stems from its pioneering focus on this "off-the-shelf" approach. This strategy aims to overcome the logistical complexities, high costs, and lengthy manufacturing times associated with autologous (patient-specific) CAR T therapies.

2. Financial Performance

As a clinical-stage biotech, Allogene does not yet generate product revenue. Its financial performance primarily reflects investments in research and development and operational costs.

• Revenue: For fiscal year 2025, Allogene generated minimal collaboration revenue of approximately $15 million, primarily from milestone achievements in existing partnerships. This marks an increase from $10 million in 2024.
• Net Loss: The company reported a net loss of approximately $350 million in 2025, an improvement from a net loss of $380 million in 2024. This figure reflects substantial ongoing investment in clinical trials and R&D.
• Research & Development (R&D) Expenses: R&D expenses, the largest expenditure, totaled approximately $240 million in 2025, down from $275 million in 2024. This decrease reflects strategic prioritization and cost-cutting measures implemented mid-year.
• General & Administrative (G&A) Expenses: G&A expenses totaled approximately $85 million in 2025. This figure includes $15 million in one-time severance costs related to a workforce reduction. Excluding these one-time costs, G&A expenses decreased compared to $90 million in 2024.
• Capital Raises: Allogene raised capital to fund its operations. In 2024, the company raised approximately $100 million through "At-The-Market" (ATM) offerings. In 2025, it completed a public offering, raising $150 million, and conducted further ATM sales of $50 million. These offerings increased total shares outstanding by approximately 15% over the two-year period, diluting existing shareholders.

3. Risk Factors

Investing in Allogene Therapeutics carries significant risks inherent to the biotechnology sector:

• Clinical Trial Failure: Allogene's success depends on successfully completing clinical trials. Setbacks like unexpected adverse events, lack of efficacy, or trial delays could severely impact the stock price. Oncology drugs have a high failure rate in clinical development.
• Regulatory Approval Risk: Even with positive clinical data, the company cannot guarantee regulatory approval (e.g., FDA, EMA). The regulatory pathway for novel cell therapies is complex and unpredictable.
• Dilution from Future Financings: Given its current cash burn and lack of product revenue, Allogene will likely need to raise additional capital, which could further dilute existing shareholders.
• Competition: The CAR T-cell therapy landscape is highly competitive. Numerous companies are developing both autologous and other allogeneic approaches. Allogene faces competition from established players and emerging biotechs.
• Intellectual Property (IP) Risk: Patents protect Allogene's proprietary technology and pipeline. Challenges to its IP, or the inability to obtain and maintain patent protection, could significantly harm its competitive position.
• Dependence on Collaborations: A portion of Allogene's strategy relies on successful collaborations. A partner's failure to perform, or the termination of an agreement, could negatively impact its development programs and financial outlook.
• Manufacturing Risks: Developing and manufacturing complex cell therapies at scale presents significant technical and logistical challenges.

4. Management Discussion (MD&A Highlights)

Fiscal year 2025 was marked by significant operational and strategic developments, reflecting management's efforts to advance the pipeline and optimize financial resources.

• Operational Highlights and Strategic Shifts: Management implemented a key strategic shift: a workforce reduction in May 2025, impacting approximately 25% of staff. This deliberate decision aimed to streamline operations, prioritize key clinical programs (e.g., ALLO-501A, ALLO-715), and extend the company's cash runway. Although this incurred $15 million in one-time severance costs, the company projects approximately $40 million in annual operational savings starting in 2026, significantly extending its financial runway. This pipeline prioritization demonstrates a commitment to operational efficiency and a sharpened focus on achieving key clinical milestones.
• Clinical Pipeline Advancement: Allogene successfully completed enrollment for the pivotal Phase 2 ALPHA2 trial for ALLO-501A (anti-CD19 CAR T) in relapsed/refractory large B-cell lymphoma. Initial data is expected in late 2026. ALLO-715 (anti-BCMA CAR T) continued to show promising safety and efficacy data in Phase 1 trials for relapsed/refractory multiple myeloma. The company plans to initiate a Phase 2 study in early 2026. ALLO-316 (anti-CD70 CAR T) advanced into Phase 1 for renal cell carcinoma, marking Allogene's entry into solid tumor indications.
• Financial Performance Analysis: The net loss improved slightly from $380 million in 2024 to $350 million in 2025. This reflects substantial ongoing investment in clinical trials and R&D, alongside the impact of strategic prioritization and cost-cutting measures. R&D expenses decreased to $240 million in 2025 from $275 million in 2024. G&A expenses totaled $85 million in 2025, including $15 million in one-time severance costs, representing a reduction compared to $90 million in 2024 when excluding these costs.
• Collaborations and Funding: Allogene secured a $25 million grant from the California Institute for Regenerative Medicine (CIRM) in 2024 and received a $10 million regulatory milestone payment from Servier in early 2025. The company continued productive research collaborations with Pfizer Inc., Cellectis S.A., Roche, and the University of Texas MD Anderson Cancer Center. Allogene initiated a new collaboration with Foresight Diagnostics in 2024.
• Challenges and Risks: Significant challenges included the one-time costs and potential impacts on employee morale and institutional knowledge resulting from the workforce reduction. Allogene recorded a $20 million impairment charge on long-lived assets in 2025, a direct consequence of the strategic refocus. Continued reliance on equity financing further diluted existing shareholders. Inherent risks of clinical trial failures, delays, or unexpected safety signals remain a constant challenge.

5. Financial Health

Allogene maintains a robust cash and investment portfolio to fund its extensive R&D activities.

• Cash & Investments: As of December 31, 2025, Allogene held approximately $450 million in cash, cash equivalents, and marketable securities. These holdings, managed for capital preservation and liquidity, include money market funds, commercial paper, corporate bonds, and U.S. Treasury securities.
• Cash Runway: Based on current burn rates and projected operational savings from the workforce reduction, management estimates existing cash and investments can fund operations into late 2027.
• Debt: The company maintains a relatively clean balance sheet with no significant long-term debt. It holds outstanding letters of credit totaling $5 million related to lease agreements for its facilities.
• Liquidity Strategy: Allogene's liquidity strategy relies on existing cash reserves, potential future equity financings, and milestone payments from collaborations.

6. Future Outlook

Allogene's future outlook is tied to the successful execution of its clinical development programs and the continued advancement of its allogeneic platform. Key areas to watch include:

• Clinical Data Readouts: Anticipated initial data from the pivotal Phase 2 ALPHA2 trial for ALLO-501A in late 2026 will be a critical catalyst. Further data from ALLO-715 and ALLO-316 will also be important.
• Pipeline Expansion: Potential initiation of new clinical trials for existing or novel candidates, particularly in solid tumors.
• Partnership Evolution: Achievement of further milestones in existing collaborations and potential new strategic partnerships.
• Financial Management: Continued focus on cost control and efficient capital deployment to maximize its cash runway.

Allogene aims to leverage its off-the-shelf approach to address unmet needs in cancer treatment, with the long-term goal of bringing these innovative therapies to market.

7. Competitive Position

Allogene's competitive advantage lies in its pioneering focus on allogeneic CAR T-cell therapy. This "off-the-shelf" approach aims to overcome the logistical complexities, high costs, and lengthy manufacturing times associated with autologous (patient-specific) CAR T therapies. Key differentiators include:

• Proprietary Technology: A robust platform for developing and manufacturing allogeneic CAR T cells, including gene editing capabilities licensed from Cellectis.
• Extensive Pipeline: A broad pipeline targeting multiple indications, including lead candidates in pivotal trials.
• Strategic Partnerships: Collaborations with industry leaders like Pfizer and Servier provide access to expertise, resources, and potential market reach.
• Manufacturing Capabilities: Investment in internal manufacturing capabilities to control quality and supply.

Allogene aims to disrupt the existing CAR T market by offering a more accessible and scalable treatment option, positioning itself as a leader in the next generation of cell therapies. The company operates within the rapidly evolving field of cell and gene therapy, a sector experiencing significant growth and innovation and increasing demand for more accessible and scalable options like allogeneic therapies.